ReviewIntractable & rare diseases research2013
Primary gastrointestinal stromal tumors: Current advances in diagnostic biomarkers, prognostic factors and management of its duodenal location.
Review in Intractable & rare diseases research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- Esophageal perforation secondary to esophageal gastrointestinal stromal tumor.JTCVS techniques · 2024Article
- Safety and efficacy of surgical and endoscopic resection in the treatment of duodenal subepithelial lesions.Surgical endoscopy · 2022Article
- Robotic Excision of a Duodenal Gastrointestinal Stromal Tumor.Annals of surgical oncology · 2021Article
- Clinical comparative analysis of various duodenal diseases in different age groups.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- Giant gastrointestinal stromal tumor of the mediastinum associated with an esophageal hiatal hernia and chest discomfort: a case report.Surgical case reports · 2018Article
- EGIST: a Rare Tumor.Journal of gastrointestinal cancer · 2018Article
- Endoscopic ultrasound-guided fine-needle aspiration for diagnosing a rare extraluminal duodenal gastrointestinal tumor.World journal of gastrointestinal endoscopy · 2017Article
- Surgery for Duodenal Gastrointestinal Stromal Tumors: A Single-Center Experience.Digestive diseases and sciences · 2017Article
- Proliferation markers RacGAP1 and Ki-67 in gastrointestinal stromal tumors by immunohistochemistry with respect to clinicopathological features and different risk stratification systems.International journal of clinical and experimental pathology · 2017Article
- Duodenal gastrointestinal stromal tumors: clinicopathological characteristics, surgery, and long-term outcome.BMC surgery · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GIST) constitute 1-3% of all gastrointestinal malignancies and is the most common mesenchymal tumor of the gastrointestinal tract. Although GIST were first described in the literature in the year 1941, important advances of kit mutation and tyrosine kinase inhibitors were not made to understand and manage GIST until the last decade. Here current advances in research of possible cellular origin, diagnostic biomarkers and prognostic factors of primary GIST are reviewed, and the management of primary duodenal GIST is focused on due to its specific location. It is possible that personalized assessment and therapy will turn out to be another milestone for primary GIST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.